Biomarin Pharmaceutical Stock Fundamentals
| BMRN Stock | USD 69.44 1.16 1.64% |
Biomarin Pharmaceutical fundamentals help investors to digest information that contributes to Biomarin Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Biomarin Stock. The fundamental analysis module provides a way to measure Biomarin Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomarin Pharmaceutical stock.
At this time, Biomarin Pharmaceutical's Operating Income is very stable compared to the past year. As of the 15th of March 2025, EBIT is likely to grow to about 581.8 M, while Non Operating Income Net Other is likely to drop about 7.1 M. Biomarin | Select Account or Indicator |
Biomarin Pharmaceutical Company Operating Margin Analysis
Biomarin Pharmaceutical's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biomarin Pharmaceutical Operating Margin | 0.34 % |
Most of Biomarin Pharmaceutical's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomarin Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Biomarin Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Biomarin Pharmaceutical has an Operating Margin of 0.3442%. This is 100.98% lower than that of the Biotechnology sector and 100.31% lower than that of the Health Care industry. The operating margin for all United States stocks is 106.25% lower than that of the firm.
Biomarin Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biomarin Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Biomarin Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomarin Pharmaceutical competition to find correlations between indicators driving Biomarin Pharmaceutical's intrinsic value. More Info.Biomarin Pharmaceutical is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biomarin Pharmaceutical is roughly 1.56 . At this time, Biomarin Pharmaceutical's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomarin Pharmaceutical's earnings, one of the primary drivers of an investment's value.Biomarin Pharmaceutical's Earnings Breakdown by Geography
Biomarin Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomarin Pharmaceutical's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomarin Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics of similar companies.Biomarin Pharmaceutical is currently under evaluation in operating margin category among its peers.
Biomarin Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Biomarin Fundamentals
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0515 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 12.72 B | ||||
| Shares Outstanding | 190.78 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 98.57 % | ||||
| Number Of Shares Shorted | 4.47 M | ||||
| Price To Earning | 220.73 X | ||||
| Price To Book | 2.34 X | ||||
| Price To Sales | 4.64 X | ||||
| Revenue | 2.85 B | ||||
| Gross Profit | 2.27 B | ||||
| EBITDA | 650.53 M | ||||
| Net Income | 426.86 M | ||||
| Cash And Equivalents | 1.27 B | ||||
| Cash Per Share | 6.85 X | ||||
| Total Debt | 602.71 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 29.66 X | ||||
| Cash Flow From Operations | 572.84 M | ||||
| Short Ratio | 2.98 X | ||||
| Earnings Per Share | 2.21 X | ||||
| Price To Earnings To Growth | 0.48 X | ||||
| Target Price | 95.68 | ||||
| Number Of Employees | 3.04 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 13.25 B | ||||
| Total Asset | 6.99 B | ||||
| Retained Earnings | (194.69 M) | ||||
| Working Capital | 2.63 B | ||||
| Current Asset | 1.09 B | ||||
| Current Liabilities | 445.46 M | ||||
| Net Asset | 6.99 B |
About Biomarin Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomarin Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomarin Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomarin Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 M | 1.4 M | |
| Total Revenue | 2.9 B | 3 B | |
| Cost Of Revenue | 580.2 M | 609.2 M | |
| Stock Based Compensation To Revenue | 0.07 | 0.11 | |
| Sales General And Administrative To Revenue | 0.19 | 0.18 | |
| Research And Ddevelopement To Revenue | 0.26 | 0.25 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 15.02 | 15.77 | |
| Ebit Per Revenue | 0.17 | 0.18 |
Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.